BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-973. [PMID: 15151956 DOI: 10.1093/annonc/mdh216] [Cited by in Crossref: 379] [Cited by in F6Publishing: 432] [Article Influence: 19.9] [Reference Citation Analysis]
Number Citing Articles
1 Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne) 2022;9:1034315. [PMID: 36569154 DOI: 10.3389/fmed.2022.1034315] [Reference Citation Analysis]
2 Hubbard JA, Wolfe RC. Management of Carcinoid Syndrome and Carcinoid Crisis in the Perioperative Environment. Journal of PeriAnesthesia Nursing 2022. [DOI: 10.1016/j.jopan.2022.08.016] [Reference Citation Analysis]
3 Yoo JJ, Jo HI, Jung EA, Lee JS, Kim SG, Kim YS, Kim BK. Evidence of nonsurgical treatment for polycystic liver disease. Ther Adv Chronic Dis 2022;13:20406223221112563. [PMID: 35898920 DOI: 10.1177/20406223221112563] [Reference Citation Analysis]
4 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Crook C, Zhang YH, Li D. Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. Drugs Aging 2022;39:257-69. [PMID: 35332446 DOI: 10.1007/s40266-022-00934-1] [Reference Citation Analysis]
7 Kaewput C, Vinjamuri S. Role of Combined 68Ga DOTA-Peptides and 18F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics 2022;12:280. [DOI: 10.3390/diagnostics12020280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kokov KV, Egorova BV, German MN, Klabukov ID, Krasheninnikov ME, Larkin-Kondrov AA, Makoveeva KA, Ovchinnikov MV, Sidorova MV, Chuvilin DY. 212Pb: Production Approaches and Targeted Therapy Applications. Pharmaceutics 2022;14:189. [PMID: 35057083 DOI: 10.3390/pharmaceutics14010189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_17-4] [Reference Citation Analysis]
10 Kabasakal L, Demirci E, Selçuk NA. Radionuclide Therapy in Neuroendocrine Tumors. Radionuclide Therapy 2022. [DOI: 10.1007/978-3-030-97220-2_9] [Reference Citation Analysis]
11 Shaikh S. Molecular Imaging Precision Medicine. Advances in Imaging 2022. [DOI: 10.1007/978-981-16-9535-3_8] [Reference Citation Analysis]
12 Kazaz SN, Öztop İ. Systemic Treatments and Related Side Effects in Neuroendocrine Tumors. Radionuclide Therapy 2022. [DOI: 10.1007/978-3-030-97220-2_10] [Reference Citation Analysis]
13 Pang L, Guo Z. Primary neuroendocrine tumors of the ovary: Management and outcomes. Cancer Med 2021;10:8558-69. [PMID: 34773393 DOI: 10.1002/cam4.4368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncol Pract 2021;:OP2100240. [PMID: 34652954 DOI: 10.1200/OP.21.00240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 La Salvia A, Sesti F, Grinzato C, Mazzilli R, Tarsitano MG, Giannetta E, Faggiano A. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. Pharmaceuticals (Basel) 2021;14:1039. [PMID: 34681263 DOI: 10.3390/ph14101039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
17 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 de Herder WW, Feelders RA, Hofland J. Medical treatment of neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research 2021;18:139-144. [DOI: 10.1016/j.coemr.2021.03.019] [Reference Citation Analysis]
19 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Ferrel B, Franko J, Tee MC. Rare case of pancreatic neuroendocrine tumour presenting as paraneoplastic hypercalcaemia. BMJ Case Rep 2021;14:e240786. [PMID: 33858893 DOI: 10.1136/bcr-2020-240786] [Reference Citation Analysis]
21 Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. J Gastrointest Oncol 2021;12:845-55. [PMID: 34012671 DOI: 10.21037/jgo-20-292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Wu W, Chen J, Bai C, Chi Y, Du Y, Feng S, Huo L, Jiang Y, Li J, Lou W, Luo J, Shao C, Shen L, Wang F, Wang L, Wang O, Wang Y, Wu H, Xing X, Xu J, Xue H, Xue L, Yang Y, Yu X, Yuan C, Zhao H, Zhu X, Zhao Y. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Journal of Pancreatology 2021;4:1-17. [DOI: 10.1097/jp9.0000000000000064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tudela-lerma M, Orcajo-rincón J, Ramón-botella E, Álvarez-luque A, Gonzalez-leyte M, Rotger-regi A, Velasco-sánchez E, Colón-rodriguez A. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2021;40:82-90. [DOI: 10.1016/j.remnie.2021.01.009] [Reference Citation Analysis]
24 Jang S, Schmitz JJ, Atwell TD, Welch TL, Welch BT, Hobday TJ, Adamo DA, Moynagh MR. Percutaneous Image-Guided Core Needle Biopsy of Neuroendocrine Tumors: How Common Is Intraprocedural Carcinoid Crisis? J Vasc Interv Radiol 2021;32:745-51. [PMID: 33608193 DOI: 10.1016/j.jvir.2021.01.264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sung MJ, Chung MJ. Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor. Korean J Pancreas Biliary Tract 2021;26:24-32. [DOI: 10.15279/kpba.2021.26.1.24] [Reference Citation Analysis]
26 D'Amico G, Uso TD, Del Prete L, Hashimoto K, Aucejo FN, Fujiki M, Eghtesad B, Sasaki K, David Kwon CH, Miller CM, Quintini C. Neuroendocrine liver metastases: The role of liver transplantation. Transplant Rev (Orlando) 2021;35:100595. [PMID: 33548685 DOI: 10.1016/j.trre.2021.100595] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Wonn SM, Pommier RF. Carcinoid Crisis: History, Dogmas, and Data. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Prinzi N, Rossi RE, Leuzzi G, Pusceddu S. NETs of the Lung. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_12] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M, Cascella T, Spreafico C, Beninato T, Coppa J, Lo Russo G, Di Bartolomeo M, de Braud F, Pusceddu S. Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clin Lung Cancer 2021;22:161-9. [PMID: 33618994 DOI: 10.1016/j.cllc.2020.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
30 Tudela-Lerma M, Orcajo-Rincón J, Ramón-Botella E, Álvarez-Luque A, González-Leyte M, Rotger-Regi A, Velasco-Sánchez E, Colón-Rodríguez A. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:82-90. [PMID: 33239249 DOI: 10.1016/j.remn.2020.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Si Y, Guan J, Xu Y, Chen K, Kim S, Zhou L, Jaskula-Sztul R, Liu XM. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics 2020;12:E1079. [PMID: 33187322 DOI: 10.3390/pharmaceutics12111079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
32 Kokov K, Demchenko A, Egorova B, Larkin A, Lyundup A, Makoveeva K, Moiseeva A, Panchenko V, Proshin M, Reshetov I, Chuvilin D. Production and Investigation of Radiopharmaceutical Nanoconstruction [212Pb]DOTATATE for Therapy of Malignant Neoplasms. J Synch Investig 2020;14:S99-S104. [DOI: 10.1134/s102745102007023x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Yasuda A, Seki T, Kitajima N, Baba T, Sasaki N, Kametani Y, Seki M, Tanaka K, Oki M. A case of insulinoma effectively treated with low‐dose diazoxide. Clin Case Rep 2020;8:1884-1889. [DOI: 10.1002/ccr3.3017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC; from the Carcinoid Syndrome Control Collaborative. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas 2020;49:1123-30. [PMID: 32991344 DOI: 10.1097/MPA.0000000000001658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Xie J, Chen P, Xie H, Sun Y, Huang Z, Wei R, Miao Z, Wang Q, Zhang SD, Wong KH, Lin Y, Huang C, Kwok HF. Exploration of gastric neuroendocrine carcinoma (GNEC) specific signaling pathways involved in chemoresistance via transcriptome and in vitro analysis. Comput Struct Biotechnol J 2020;18:2610-20. [PMID: 33033581 DOI: 10.1016/j.csbj.2020.09.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lee H, Eads JR, Pryma DA. 68 Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors. Oncologist 2021;26:21-9. [PMID: 32886441 DOI: 10.1634/theoncologist.2020-0165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 Feng X, Wei G, Wang W, Zhang Y, Zeng Y, Chen M, Chen Y, Chen J, Zhou Z, Li Y. Nomogram for individually predicting overall survival in rectal neuroendocrine tumours. BMC Cancer 2020;20:865. [PMID: 32907602 DOI: 10.1186/s12885-020-07328-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wu W, Zhou Y, Wang Y, Liu L, Lou J, Deng Y, Zhao P, Shao A. Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma. Front Oncol 2020;10:1633. [PMID: 33014821 DOI: 10.3389/fonc.2020.01633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
39 Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther 2021;28:799-812. [PMID: 32684623 DOI: 10.1038/s41417-020-0196-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
40 Marincola Smith P, Baechle J, Solórzano CC, Tan M, Lopez-Aguiar AG, Dillhoff M, Beal E, Poultsides G, Cannon JGD, Rocha FG, Crown A, Cho C, Beems M, Winslow ER, Rendell VR, Krasnick BA, Fields RC, Maithel SK, Bailey CE, Idrees K. Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. HPB (Oxford) 2020;22:1042-50. [PMID: 31806388 DOI: 10.1016/j.hpb.2019.10.2441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights. Onco Targets Ther. 2020;13:3545-3555. [PMID: 32431509 DOI: 10.2147/ott.s202867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
42 Sabet A, Haghighiabyaneh M, Rajyaguru C, Raisinghani A, Kupsky D, Demaria AN. Carcinoid Heart Disease. Structural Heart 2020;4:78-86. [DOI: 10.1080/24748706.2020.1715517] [Reference Citation Analysis]
43 Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci 2020;21:E1682. [PMID: 32121432 DOI: 10.3390/ijms21051682] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 21.7] [Reference Citation Analysis]
44 Harris AG, Vinik AI, OʼDorisio TM, OʼDorisio MS. Radioligand Theranostics in the Management of Neuroendocrine Tumors. Pancreas 2020;49:599-603. [PMID: 32433395 DOI: 10.1097/MPA.0000000000001546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Nikiforchin A, Peng R, Sittig M, Kotiah S. A Rare Case of Metastatic Heterogeneous Poorly Differentiated Neuroendocrine Carcinoma of Ileum: A Case Report and Literature Review. J Med Cases 2020;11:6-11. [PMID: 34434328 DOI: 10.14740/jmc3401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Whyand T, Bouvier C, Davies P. Prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues. Br J Nurs. 2018;27:738-744. [PMID: 29995506 DOI: 10.12968/bjon.2018.27.13.738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
48 Jhawar S, Lakhotia R, Suzuki M, Welch J, Agarwal SK, Sharretts J, Merino M, Ahlman M, Blau JE, Simonds WF, Del Rivero J. Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1. Endocrinol Diabetes Metab Case Rep 2019;2019:EDM190040. [PMID: 31480016 DOI: 10.1530/EDM-19-0040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Braga TL, Pinto SR, dos Reis SRR, Portilho FL, da Silva de Barros AO, Bernardes ES, dos Santos SN, Alencar LMR, Ricci-junior E, Santos-oliveira R. Octreotide Nanoparticles Showed Affinity for In Vivo MIA Paca-2 Inducted Pancreas Ductal Adenocarcinoma Mimicking Pancreatic Polypeptide-Secreting Tumor of the Distal Pancreas (PPoma). Pharm Res 2019;36. [DOI: 10.1007/s11095-019-2678-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Santos AP, Vinagre J, Soares P, Claro I, Sanches AC, Gomes L, Fernandes I, Catarino AL, Preto J, Pereira BD, Marques AP, Rodrigues F, Amaral C, Rocha G, Mellidez JC, Simões H, Lopes JM, Bugalho MJ; On behalf of the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism . Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. Int J Endocrinol 2019;2019:4518742. [PMID: 31467527 DOI: 10.1155/2019/4518742] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
51 Biliotti G, Martini F, Vaggelli L, Messerini L, Colagrande S, Pupi A, Seghi P. Multiple Effects of Somatostatin Analogs Verified in Three Cases of Metastasized Neuroendocrine Tumors of the Gastroenteropancreatic System. Tumori 2006;92:170-4. [DOI: 10.1177/030089160609200214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
52 Si Y, Kim S, Guenter R, Ou J, Lu Y, Chen K, Zhang J, Whitt J, Carter AM, Bibb JA, Jaskula-sztul R, Markert JM, Zhou L, Chen H, “Margaret” Liu X. Anti-SSTR2 Antibody-Drug Conjugate for Neuroendocrine Cancer Therapy.. [DOI: 10.1101/688184] [Reference Citation Analysis]
53 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
54 Ito T, Tori M, Hashigaki S, Kimura N, Sato K, Ohki E, Sawaki A, Okusaka T. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study. Jpn J Clin Oncol 2019;49:354-60. [PMID: 30834940 DOI: 10.1093/jjco/hyz009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Clement DS, Tesselaar ME, van Leerdam ME, Srirajaskanthan R, Ramage JK. Nutritional and vitamin status in patients with neuroendocrine neoplasms. World J Gastroenterol 2019; 25(10): 1171-1184 [PMID: 30886501 DOI: 10.3748/wjg.v25.i10.1171] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
56 Sun Y, Lohse C, Smyrk T, Hobday T, Kroneman T, Zhang L. The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors. Am J Surg Pathol 2018;42:247-55. [PMID: 29016403 DOI: 10.1097/PAS.0000000000000968] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
57 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
58 Chuvilin D, Kokov K, Egorova B, Makoveeva K, Perminov Y, Proshin M. Synthesis and investigation of a preparation based on 212Pb-labeled DOTATATE synthetic peptide for therapy of neuroendocrine tumors. AIP Conference Proceedings 2019. [DOI: 10.1063/1.5099613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Qu X, Liu Z, Ma B, Li N, Zhao H, Yang T, Xue Y, Zhang X, Shao Y, Chang Y, Xu J, Lei B, Du Y. All in one theranostic nanoplatform enables efficient anti-tumor peptide delivery for triple-modal imaging guided cancer therapy. Nano Res 2019;12:593-9. [DOI: 10.1007/s12274-018-2261-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
60 Lesén E, Björstad Å, Björholt I, Marlow T, Bollano E, Feuilly M, Marteau F, Welin S, Elf AK, Johanson V. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol 2018;53:1509-18. [PMID: 30449217 DOI: 10.1080/00365521.2018.1531653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
61 Öberg K. The Genesis of the Neuroendocrine Tumors Concept. Endocrinology and Metabolism Clinics of North America 2018;47:711-31. [DOI: 10.1016/j.ecl.2018.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
62 de Herder WW. When and How to Use Somatostatin Analogues. Endocrinology and Metabolism Clinics of North America 2018;47:549-55. [DOI: 10.1016/j.ecl.2018.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
63 Deldycke A, Haenebalcke C, Taes Y. Paraneoplastic Cushing syndrome, case-series and review of the literature. Acta Clin Belg 2018;73:298-304. [PMID: 28895465 DOI: 10.1080/17843286.2017.1373927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
64 Melosky B. Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr Oncol 2018;25:S86-93. [PMID: 29910651 DOI: 10.3747/co.25.3808] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
65 Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, Kaneta T, Mori R, Matsuyama R, Endo I, Yamanaka S, Nakajima A, Inoue T, Ichikawa Y. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors. Digestion 2017;96:13-20. [PMID: 28609761 DOI: 10.1159/000470838] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
66 Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer 2018;124:1992-2000. [PMID: 29451701 DOI: 10.1002/cncr.31192] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
67 Doi R. Rare Neuroendocrine Tumors of the Pancreas. The Pancreas 2018. [DOI: 10.1002/9781119188421.ch135] [Reference Citation Analysis]
68 Öberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg 2018;7:20-7. [PMID: 29629316 DOI: 10.21037/gs.2017.10.08] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
69 Sclafani F, Carnaghi C, Di Tommaso L, Rodari M, Destro A, Rimassa L, Giordano L, Chiti A, Roncalli M, Santoro A. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Tumori 2011;97:620-8. [DOI: 10.1177/030089161109700514] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
70 Rinke A, Ricci S, Bajetta E, Jelic S. 9. Pharmacological Therapy of Neuroendocrine Tumors. Tumori 2010;96:847-57. [DOI: 10.1177/030089161009600538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
71 Leon A, Torta M, Dittadi R, Uberti ED, Ambrosio M, Fave GD, De Braud F, Tomassetti P, Gion M, Dogliotti L. Comparison between Two Methods in the Determination of Circulating Chromogranin A in Neuroendocrine Tumors (NETs): Results of a Prospective Multicenter Observational Study. Int J Biol Markers 2005;20:156-68. [DOI: 10.1177/172460080502000303] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
72 Ligiero Braga T, Santos-Oliveira R. PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment. Diseases 2018;6:E8. [PMID: 29324681 DOI: 10.3390/diseases6010008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
73 Alexander ES, Soulen MC. Liver-Directed Therapies for Neuroendocrine Metastases. Primary and Metastatic Liver Tumors 2018. [DOI: 10.1007/978-3-319-91977-5_21] [Reference Citation Analysis]
74 Sanguinetti A, Polistena A, Johnson LB, Avenia N. Pancreatic Neuroendocrine Tumors (pNETs). Surgical Management of Elderly Patients 2018. [DOI: 10.1007/978-3-319-60861-7_9] [Reference Citation Analysis]
75 Ettorre GM, Meniconi RL, Hammel P, Deguelte S, Filippi L, Cianni R. Management of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_13] [Reference Citation Analysis]
76 Rossi RE, Massironi S. Tumor Staging: Pancreas. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_15] [Reference Citation Analysis]
77 Ferone D, Nazzari E, Grillo F, Sciallero S, Morbelli S, De Cian F, Cittadini G, Albertelli M, Edoardo G. Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up. Atlas of Thyroid and Neuroendocrine Tumor Markers 2018. [DOI: 10.1007/978-3-319-62506-5_14] [Reference Citation Analysis]
78 Carlini M, Spoletini D, Grieco M, Apa D, Appetecchia M, Lauretta R, Palazzo S, Minardi S, Severi S, lanniello A. Management of Ileal, Appendiceal and Colorectal Neuroendocrine Tumors. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_12] [Reference Citation Analysis]
79 Kidd M, Ferone D, Albertelli M, Nazzari E, Bodei L, Modlin IM. The Molecular Biology of NET: Current Status and Evaluation of Biomarkers for Prediction and Prognosis. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_3] [Reference Citation Analysis]
80 Elgendy AA, MacDonald W, Whitnah J, Malone D, Johnson B, Huq N. Hindgut gastropancreatic neuroendocrine carcinoma mimicking hydatid disease. Radiol Case Rep 2018;13:186-90. [PMID: 29487655 DOI: 10.1016/j.radcr.2017.10.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Bisht N, Singh S, Sarin A, Madakshira MG, Mulajker D. Neuroendocrine tumor of the inguinal node: A very rare presentation. Journal of Oncological Sciences 2017;3:137-139. [DOI: 10.1016/j.jons.2017.08.005] [Reference Citation Analysis]
82 Borna RM, Jahr JS, Kmiecik S, Mancuso KF, Kaye AD. Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks. Anesthesiol Clin. 2017;35:327-339. [PMID: 28526153 DOI: 10.1016/j.anclin.2017.01.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
83 Cioppi F, Cianferotti L, Masi L, Giusti F, Brandi ML. The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome. Clin Cases Miner Bone Metab 2017;14:123-30. [PMID: 29263719 DOI: 10.11138/ccmbm/2017.14.1.123] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
84 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
85 Huguet I, Grossman A. MANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts. Eur J Endocrinol 2017;177:R219-29. [PMID: 28982960 DOI: 10.1530/EJE-17-0295] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
86 Öberg K. Medical Therapy of Gastrointestinal Neuroendocrine Tumors. Visc Med 2017;33:352-6. [PMID: 29177164 DOI: 10.1159/000475831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
87 Hodul P, Malafa M, Choi J, Kvols L. The Role of Cytoreductive Hepatic Surgery as an Adjunct to the Management of Metastatic Neuroendocrine Carcinomas. Cancer Control 2017;13:61-71. [DOI: 10.1177/107327480601300109] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
88 Enzler T, Fojo T. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Semin Oncol. 2017;44:141-156. [PMID: 28923213 DOI: 10.1053/j.seminoncol.2017.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
89 Ma Z, Cai H, Cui Y. Progress in the treatment of esophageal neuroendocrine carcinoma. Tumour Biol. 2017;39:1010428317711313. [PMID: 28653897 DOI: 10.1177/1010428317711313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
90 Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, Cuthbertson DJ, Dobson R, Grozinsky-Glasberg S, Steeds RP, Dreyfus G, Pellikka PA, Toumpanakis C. Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement. J Am Coll Cardiol 2017;69:1288-304. [PMID: 28279296 DOI: 10.1016/j.jacc.2016.12.030] [Cited by in Crossref: 124] [Cited by in F6Publishing: 130] [Article Influence: 20.7] [Reference Citation Analysis]
91 Del Prete M, Di Sarno A, Modica R, Lassandro F, Giorgio A, Bianco A, Muto M, Gasperi M, Del Prete F, Colao A, Montesarchio V, Faggiano A; ENETS Centre of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. J Endocrinol Invest 2017;40:1373-80. [DOI: 10.1007/s40618-017-0723-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
92 Fan JH, Zhang YQ, Shi SS, Chen YJ, Yuan XH, Jiang LM, Wang SM, Ma L, He YT, Feng CY, Sun XB, Liu Q, Deloso K, Chi Y, Qiao YL. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget. 2017;8:71699-71708. [PMID: 29069739 DOI: 10.18632/oncotarget.17599] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
93 Tonelli F, Marini F, Giusti F, Brandi ML. Gastro-entero-pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: a therapy update. International Journal of Endocrine Oncology 2017;4:43-58. [DOI: 10.2217/ije-2016-0017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
94 Yalchin M, Oliveira A, Theocharidou E, Pencharz D, Navalkissoor S, Quigley A, Walker M, Caplin M, Toumpanakis C. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors. Clinical Nuclear Medicine 2017;42:e135-41. [DOI: 10.1097/rlu.0000000000001457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
95 Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017;22:272-85. [PMID: 28220021 DOI: 10.1634/theoncologist.2016-0305] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
96 Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20 [PMID: 28144395 DOI: 10.4251/wjgo.v9.i1.4] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
97 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26067-9_17-3] [Reference Citation Analysis]
98 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26067-9_17-2] [Reference Citation Analysis]
99 Carey TC. Carcinoid Disease. Anesthesiology 2017. [DOI: 10.1007/978-3-319-50141-3_33] [Reference Citation Analysis]
100 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26236-9_17] [Reference Citation Analysis]
101 Gurevich LE, Korsakova NA, Voronkova IA, Ashevskaya  VE, Titov AG, Kogoniya LM, Egorov AV, Britvin TA, Vasil'ev IA. IMMUNOHISTOCHEMICAL DETERMINATION OF EXPRESSION OF SOMATOSTATIN RECEPTORS TYPES 1, 2A, 3 AND 5 IN NEUROENDOCRINE TUMORS OF VARIOUS LOCALIZATION AND GRADE. Alʹm klin med 2016;44:378-390. [DOI: 10.18786/2072-0505-2016-44-4-378-390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
102 Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget 2016;7:5538-47. [PMID: 26701729 DOI: 10.18632/oncotarget.6686] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
103 Peker A, Çiçek O, Soydal Ç, Küçük NÖ, Bilgiç S. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol. 2015;21:54-59. [PMID: 25430526 DOI: 10.5152/dir.2014.14036] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
104 Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016;17:2487-2498. [PMID: 27817224 DOI: 10.1080/14656566.2016.1254191] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
105 Riechelmann RP, Pereira AA, Rego JF, Costa FP. Refractory carcinoid syndrome: A review of treatment options. Ther Adv Med Oncol. 2017;9:127-137. [PMID: 28203303 DOI: 10.1177/1758834016675803] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
106 Chung C. Management of neuroendocrine tumors. American Journal of Health-System Pharmacy 2016;73:1729-44. [DOI: 10.2146/ajhp150373] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
107 Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;30:163-77. [PMID: 26614375 DOI: 10.1016/j.hoc.2015.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
108 Pereira JA, Rosado E, Bali M, Metens T, Chao SL. Pancreatic neuroendocrine tumors: correlation between histogram analysis of apparent diffusion coefficient maps and tumor grade. Abdom Imaging 2015;40:3122-8. [PMID: 26280127 DOI: 10.1007/s00261-015-0524-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
109 Basuroy R, Srirajaskanthan R, Ramage JK. Neuroendocrine Tumors. Gastroenterol Clin North Am 2016;45:487-507. [PMID: 27546845 DOI: 10.1016/j.gtc.2016.04.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
110 Paul D, Ostwal V, Bose S, Basu S, Gupta S. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective. Eur J Gastroenterol Hepatol 2016;28:985-90. [PMID: 27257869 DOI: 10.1097/MEG.0000000000000674] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
111 Halpin K, McDonough R, Alba P, Halpin J, Singh V, Yan Y. Vague neuroglycopenic complaints camouflage diagnosis of adolescent insulinoma: a case report. Int J Pediatr Endocrinol 2016;2016:14. [PMID: 27478444 DOI: 10.1186/s13633-016-0032-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
112 Roviello G, Zanotti L, Venturini S, Bottini A, Generali D. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. Cancer Biol Ther 2016;17:883-8. [PMID: 27414404 DOI: 10.1080/15384047.2016.1210735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
113 Ishizu S, Setoyama T, Ueo T, Ueda Y, Kodama Y, Ida H, Kawaguchi Y, Yoshizawa A, Chiba T, Miyamoto S. Concomitant Case of Intraductal Papillary Mucinous Neoplasm of the Pancreas and Functioning Pancreatic Neuroendocrine Tumor (Vasoactive Intestinal Polypeptide-Producing Tumor): First Report. Pancreas 2016;45:e24-5. [PMID: 27295534 DOI: 10.1097/MPA.0000000000000578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
114 Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Endocrinol Metab 2016;11:311-27. [PMID: 30058926 DOI: 10.1080/17446651.2016.1199952] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Basu S, Ranade R, Ostwal V, Shrikhande SV. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics 2016;11:233-41. [DOI: 10.1016/j.cpet.2016.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
116 Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol 2016;13:691-705. [PMID: 27273044 DOI: 10.1038/nrclinonc.2016.85] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
117 Gut P, Waligórska-Stachura J, Czarnywojtek A, Sawicka-Gutaj N, Bączyk M, Ziemnicka K, Fischbach J, Woliński K, Kaznowski J, Wrotkowska E, Ruchała M. Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci 2017;13:515-24. [PMID: 28507564 DOI: 10.5114/aoms.2016.60311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
118 Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 2016;3:175-89. [PMID: 27347369 DOI: 10.2217/ije-2015-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
119 Fabian E, Haas B, Kump P, Lipp R, Kornprat P, Lutfi A, Talakic E, Fuchsjäger M, Spindelboeck W, Lackner C, Zollner G, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver. Wien Klin Wochenschr 2016;128:277-86. [PMID: 26919853 DOI: 10.1007/s00508-016-0965-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
120 Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T. Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer 2016;16:156. [PMID: 26915359 DOI: 10.1186/s12885-016-2159-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
121 Chan JA, Kulke MH. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy. Surg Oncol Clin N Am 2016;25:423-37. [PMID: 27013373 DOI: 10.1016/j.soc.2015.11.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
122 Tancredi A, Muscarella LA, la Torre A, Scaramuzzi R, Valori VM, Fazio VM, Scaramuzzi G. The Post-Surgical Long-Term Behaviour of Lung Carcinoid Tumours. Indian J Surg 2015;77:481-5. [PMID: 26884654 DOI: 10.1007/s12262-015-1290-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Smith TL, Yuan Z, Cardó-Vila M, Sanchez Claros C, Adem A, Cui MH, Branch CA, Gelovani JG, Libutti SK, Sidman RL, Pasqualini R, Arap W. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proc Natl Acad Sci U S A 2016;113:2466-71. [PMID: 26884209 DOI: 10.1073/pnas.1525709113] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
124 Song KB, Kim SC, Kim JH, Seo DW, Hong SM, Park KM, Hwang DW, Lee JH, Lee YJ. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors. Pancreas 2016;45:187-92. [PMID: 26474434 DOI: 10.1097/MPA.0000000000000493] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
125 Hendifar AE, Liu S, Wolin E. The Role of mTOR Inhibitors in Neuroendocrine Tumors. mTOR Inhibition for Cancer Therapy: Past, Present and Future 2016. [DOI: 10.1007/978-2-8178-0492-7_5] [Reference Citation Analysis]
126 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2016. [DOI: 10.1007/978-3-319-26067-9_17-1] [Reference Citation Analysis]
127 Fazio N, Spada F. Management of Neuroendocrine Tumors. PET/CT in Neuroendocrine Tumors 2016. [DOI: 10.1007/978-3-319-29203-8_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Sliesoraitis S, George TJ. Chemotherapy. Pancreatic Masses 2016. [DOI: 10.1007/978-3-319-19677-0_19] [Reference Citation Analysis]
129 Nasir A, Sheikh U, Muhammad J, Coppola D. Somatostatin Receptors in Human Neuroendocrine Tumors. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances 2016. [DOI: 10.1007/978-1-4939-3426-3_24] [Reference Citation Analysis]
130 Rinke A, Krug S. Neuroendocrine tumours – Medical therapy: Biological. Best Practice & Research Clinical Endocrinology & Metabolism 2016;30:79-91. [DOI: 10.1016/j.beem.2015.09.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
131 Spaulding T, Martin RCG. Gastrointestinal Neuroendocrine Tumors: Optimal Outcomes and Surgical Management. Current Controversies in Cancer Care for the Surgeon 2016. [DOI: 10.1007/978-3-319-16205-8_3] [Reference Citation Analysis]
132 Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F. Pancreatic neuroendocrine tumors: Nosography, management and treatment. Int J Surg. 2016;28 Suppl 1:S156-S162. [PMID: 26708853 DOI: 10.1016/j.ijsu.2015.12.052] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
133 Okuma Y, Hosomi Y, Watanabe K, Takahashi S, Okamura T, Hishima T. Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. Int J Clin Oncol 2016;21:531-8. [PMID: 26646221 DOI: 10.1007/s10147-015-0926-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
134 Temmerman F, Ho TA, Vanslembrouck R, Coudyzer W, Billen J, Dobbels F, van Pelt J, Bammens B, Pirson Y, Nevens F. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease. Clin Gastroenterol Hepatol 2015;13:2353-9.e1. [PMID: 26073493 DOI: 10.1016/j.cgh.2015.05.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
135 Athiyappan K, Ramachandran R, Rajendiran S, Thangam V. Incidental Detection of Neuroendocrine Carcinoma of Rectum During Staging Workup of Renal Cell Carcinoma. World J Oncol 2015;6:491-4. [PMID: 28983352 DOI: 10.14740/wjon949w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 Carolan PJ, Chung DC. Neuroendocrine Tumors of the Pancreas. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch88] [Reference Citation Analysis]
137 Massironi S, Conte D, Rossi RE. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scand J Gastroenterol 2016;51:513-23. [PMID: 26605828 DOI: 10.3109/00365521.2015.1115117] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
138 Riff BP, Yang Y, Soulen MC, Pryma DA, Bennett B, Wild D, Nicolas G, Teitelbaum UR, Metz DC. Peptide Receptor Radionuclide Therapy–Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors. Clinical Nuclear Medicine 2015;40:845-50. [DOI: 10.1097/rlu.0000000000000935] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
139 Tamburrino D, Spoletini G, Partelli S, Muffatti F, Adamenko O, Crippa S, Falconi M. Surgical management of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2016;30:93-102. [PMID: 26971846 DOI: 10.1016/j.beem.2015.10.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
140 Jiménez-fonseca P, Carmona-bayonas A, Martín-pérez E, Crespo G, Serrano R, Llanos M, Villabona C, García-carbonero R, Aller J, Capdevila J, Grande E; On behalf of the Spanish Neuroendocrine Tumor Group (GETNE). Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev 2015;34:381-400. [DOI: 10.1007/s10555-015-9573-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
141 Yuvaraj A, Abraham G, Kurien A, Koshy P, Nair S, Ghosh S. A maintenance hemodialysis diabetic patient with unexplained pulmonary and gastrointestinal involvement. Hemodial Int 2016;20:E12-5. [PMID: 26198989 DOI: 10.1111/hdi.12337] [Reference Citation Analysis]
142 de Herder WW. Somatostatin Analogues in Pharmacotherapy. Somatostatin Analogues 2015. [DOI: 10.1002/9781119031659.ch14] [Reference Citation Analysis]
143 de Herder WW. Somatostatin Analogues in Pharmacotherapy. Somatostatin Analogues 2015. [DOI: 10.1002/9781119031659.ch15] [Reference Citation Analysis]
144 Cives M, Strosberg J. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs 2015;75:847-58. [DOI: 10.1007/s40265-015-0397-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
145 Igarashi H, Hijioka M, Lee L, Ito T. Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs. J Hepatobiliary Pancreat Sci 2015;22:618-22. [PMID: 25689143 DOI: 10.1002/jhbp.227] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
146 Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
147 Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol 2015;1:131-53. [PMID: 28210673 DOI: 10.1016/j.jcmgh.2014.12.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
148 Strosberg J. Somatostatin Analogs and Interferon in the Treatment of Neuroendocrine Tumors. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_30] [Reference Citation Analysis]
149 E28 Literaturhinweise und Internetadressen. Facharzt Hämatologie Onkologie 2015. [DOI: 10.1016/b978-3-437-21213-0.16001-2] [Reference Citation Analysis]
150 Cremer B, Anlauf M. Neuroendokrine Neoplasien des Jejunums und Ileums. DGIM Innere Medizin 2015. [DOI: 10.1007/978-3-642-54676-1_510-1] [Reference Citation Analysis]
151 Koumarianou A, Fazio N. Nonfunctioning Pancreatic Neuroendocrine Tumors. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_18] [Reference Citation Analysis]
152 Kilickap S, Yalcin S. Carcinoid Syndrome. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
153 Avendaño C, Menéndez JC. Anticancer Drugs That Modulate Hormone Action. Medicinal Chemistry of Anticancer Drugs 2015. [DOI: 10.1016/b978-0-444-62649-3.00003-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
154 Göke B, Hoffmann J. Neuroendokrine Tumoren des Gastrointestinaltrakts. Viszeralmedizin 2015. [DOI: 10.1007/978-3-642-14301-4_39] [Reference Citation Analysis]
155 Kondo NI, Ikeda Y. Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg. 2014;3:276-283. [PMID: 25493259 DOI: 10.3978/j.issn.2227-684x.2013.12.05] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
156 Raymond E, Faivre S. Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours. Curr Oncol. 2014;21:309-317. [PMID: 25489258 DOI: 10.3747/co.21.1647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
157 Mapelli P, Aboagye EO, Stebbing J, Sharma R. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene 2015;34:4439-47. [DOI: 10.1038/onc.2014.379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
158 Okuma Y, Hosomi Y, Takahashi S, Maeda Y, Okamura T, Hishima T. Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma. Clin Lung Cancer 2015;16:221-7. [PMID: 25468802 DOI: 10.1016/j.cllc.2014.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
159 Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M. Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. World J Radiol 2014; 6(10): 840-845 [PMID: 25349667 DOI: 10.4329/wjr.v6.i10.840] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
160 Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med 2013;1:6. [PMID: 25332951 DOI: 10.3978/j.issn.2305-5839.2013.01.08] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
161 Rossi RE, Massironi S, Conte D, Peracchi M. Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med 2014;2:8. [PMID: 25332984 DOI: 10.3978/j.issn.2305-5839.2013.03.01] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
162 Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015;121:1172-86. [PMID: 25274401 DOI: 10.1002/cncr.28760] [Cited by in Crossref: 109] [Cited by in F6Publishing: 127] [Article Influence: 12.1] [Reference Citation Analysis]
163 Salyers WJ, Vega KJ, Munoz JC, Trotman BW, Tanev SS. Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review. World J Gastrointest Oncol 2014; 6(8): 301-310 [PMID: 25132927 DOI: 10.4251/wjgo.v6.i8.301] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
164 Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930-936. [PMID: 25096997 DOI: 10.1634/theoncologist.2014-0120] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 7.9] [Reference Citation Analysis]
165 Sainz-Esteban A, Baum RP. Successful treatment of metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor unresponsive to high-dose octreotide by peptide receptor radionuclide therapy using 90Y DOTATATE. Clin Nucl Med 2013;38:996-7. [PMID: 24212444 DOI: 10.1097/RLU.0b013e3182a7596b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
166 Kamp K, Feelders RA, van Adrichem RC, de Rijke YB, van Nederveen FH, Kwekkeboom DJ, de Herder WW. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. J Clin Endocrinol Metab. 2014;99:3060-3069. [PMID: 24905065 DOI: 10.1210/jc.2014-1315] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
167 Prasad V, Bodei L, Kidd M, Modlin IM. Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths. Eur J Nucl Med Mol Imaging 2014;41:1825-30. [DOI: 10.1007/s00259-014-2780-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
168 Zeng YJ, Lai W, Liu L, Wu H, Luo XX, Wang J, Chu ZH. Prognostic significance of neuroendocrine differentiation in colorectal adenocarcinoma after radical operation: a meta-analysis. J Gastrointest Surg 2014;18:968-76. [PMID: 24549474 DOI: 10.1007/s11605-014-2480-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
169 de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol 2014;170:R173-83. [PMID: 24723670 DOI: 10.1530/EJE-14-0077] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
170 Ameri P, Gatto F, Arvigo M, Villa G, Resmini E, Minuto F, Murialdo G, Ferone D. Somatostatin receptor scintigraphy in thoracic diseases. J Endocrinol Invest 2007;30:889-902. [DOI: 10.1007/bf03349233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
171 Meeker A, Heaphy C. Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology 2014;386:101-20. [DOI: 10.1016/j.mce.2013.07.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
172 Ronchi CL, Peracchi M, Corbetta S, Massironi S, Ciafardini C, Conte D, Beck-peccoz P, Spada A. Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors. J Endocrinol Invest 2007;30:241-6. [DOI: 10.1007/bf03347432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
173 Costa F, Gumz B. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours. Eur Endocrinol 2014;10:70-4. [PMID: 29872467 DOI: 10.17925/EE.2014.10.01.70] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
174 Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7. [PMID: 24570674 DOI: 10.3389/fendo.2014.00007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
175 Frilling A, Weber F, Cicinnati V, Broelsch C. Role of radiolabeled octreotide therapy in patients with metastatic neuroendocrine neoplasms. Expert Rev Endocrinol Metab 2007;2:517-27. [PMID: 30290419 DOI: 10.1586/17446651.2.4.517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
176 Öberg K. Molecular imaging of neuroendocrine tumors. Expert Review of Endocrinology & Metabolism 2014;3:739-49. [DOI: 10.1586/17446651.3.6.739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Öberg K. Somatostatin analog octreotide LAR ® in gastro–entero–pancreatic tumors. Expert Review of Anticancer Therapy 2014;9:557-66. [DOI: 10.1586/era.09.26] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
178 John BJ, Davidson BR. Treatment options for unresectable neuroendocrine liver metastases. Expert Review of Gastroenterology & Hepatology 2014;6:357-69. [DOI: 10.1586/egh.11.60] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
179 Öberg KE. Management of neuroendocrine tumors: current and future therapies. Expert Review of Endocrinology & Metabolism 2014;6:49-62. [DOI: 10.1586/eem.10.81] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
180 Zitzmann K, Vlotides G, Göke B, Auernhammer CJ. PI(3)K–Akt–mTOR pathway as a potential therapeutic target in neuroendocrine tumors. Expert Review of Endocrinology & Metabolism 2014;3:207-22. [DOI: 10.1586/17446651.3.2.207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
181 Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol 2014; 20(1): 118-125 [PMID: 24415864 DOI: 10.3748/wjg.v20.i1.118] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
182 Lewis BS, Keuchel M, Wiedbrauck F, Caselitz J, Kakugawa Y, Saito Y. Malignant Tumors. Video Capsule Endoscopy 2014. [DOI: 10.1007/978-3-662-44062-9_34] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Neuzillet C, Hentic O, Raymond E, Ruszniewski P. Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors. Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract 2014. [DOI: 10.1007/978-2-8178-0430-9_4] [Reference Citation Analysis]
184 Imamura H, Hashimoto T, Yamaguchi I, Itoh Y, Furui J. An Insulinoma in which Glycemic Fluctuation was Successfully Managed Preoperatively by Octreotide Subcutaneous Injections. Jpn J Gastroenterol Surg 2014;47:596-601. [DOI: 10.5833/jjgs.2013.0281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
185 Du SD, Wang Z, Mao YL. Therapeutic advances in neuroendocrine neoplasms with hepatic metastases. Shijie Huaren Xiaohua Zazhi 2013; 21(36): 4069-4074 [DOI: 10.11569/wcjd.v21.i36.4069] [Reference Citation Analysis]
186 Wang L, Tang K, Zhang Q, Li H, Wen Z, Zhang H, Zhang H. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. Biomed Res Int. 2013;2013:102819. [PMID: 24106690 DOI: 10.1155/2013/102819] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
187 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
188 Rodrigues P, Castedo JL, Damasceno M, Carvalho D. Ectopic Cushing's syndrome caused by a pulmonary ACTH-secreting tumor in a patient treated with octreotide. Arq Bras Endocrinol Metabol 2012;56:461-4. [PMID: 23108752 DOI: 10.1590/s0004-27302012000700009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
189 Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56-68. [PMID: 23391113 DOI: 10.1053/j.seminoncol.2012.11.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
190 Okuma Y, Hosomi Y, Takagi Y, Sasaki E, Hishima T, Maeda Y, Shibuya M, Okamura T. Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer 2013;80:75-80. [DOI: 10.1016/j.lungcan.2012.12.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
191 Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K. Diagnosis and management of insulinoma. World J Gastroenterol 2013; 19(6): 829-837 [PMID: 23430217 DOI: 10.3748/wjg.v19.i6.829] [Cited by in CrossRef: 194] [Cited by in F6Publishing: 208] [Article Influence: 19.4] [Reference Citation Analysis]
192 Macedo D, Amaral T, Fernandes I, Sousa AR, Costa AL, Távora I, Quintela A, Cortes P, Costa L. The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. ISRN Hepatol 2013;2013:702167. [PMID: 27335831 DOI: 10.1155/2013/702167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
193 Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii124-vii130. [PMID: 22997445 DOI: 10.1093/annonc/mds295] [Cited by in Crossref: 307] [Cited by in F6Publishing: 351] [Article Influence: 30.7] [Reference Citation Analysis]
194 Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V, Vullierme MP, Couvelard A, Hentic O, Ruszniewski P. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. Eur J Gastroenterol Hepatol 2013;25:232-8. [PMID: 23108416 DOI: 10.1097/MEG.0b013e328359d1a6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 5.1] [Reference Citation Analysis]
195 Rahbour G, Siddiqui MR, Ullah MR, Gabe SM, Warusavitarne J, Vaizey CJ. A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas. Ann Surg 2012;256:946-54. [PMID: 22885696 DOI: 10.1097/SLA.0b013e318260aa26] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
196 Arnold R, Langer P, Rothmund M, Klöppel G, Kann P, Heverhagen J, Fendrich V, Bartsch D, Rinke A, Müller X, Klose K, Brenner W, Prasad V, Wiedenmann B, Jann H, Gress T, Pascher A, Neuhaus P, Habbe N, Simon B, Stinner B. Endokrine Tumoren des gastroenteropankreatischen Systems. Praxis der Viszeralchirurgie 2013. [DOI: 10.1007/978-3-642-14285-7_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
197 Sowa-Staszczak A, Hubalewska-Dydejczyk A, Tomaszuk M. PRRT as neoadjuvant treatment in NET. Recent Results Cancer Res 2013;194:479-85. [PMID: 22918777 DOI: 10.1007/978-3-642-27994-2_27] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
198 Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013;31:1265-74. [PMID: 23269537 DOI: 10.1007/s10637-012-9910-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
199 Gulati AP, Krantz B, Moss RA, Moyal WN, Tsushima DA, Mowatt KB, Schreibman S, Fine RL. Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology 2013;84:127-34. [PMID: 23235517 DOI: 10.1159/000342961] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
200 Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol 2012;26:755-73. [PMID: 23582917 DOI: 10.1016/j.bpg.2012.12.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
201 Wang YH, Lin Y, Xue L, Wang JH, Chen MH, Chen J. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord. 2012;12:30. [PMID: 23194346 DOI: 10.1186/1472 -6823-12-30] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
202 Wang YH, Lin Y, Xue L, Wang JH, Chen MH, Chen J. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord. 2012;12:30. [PMID: 23194346 DOI: 10.1186/1472-6823-12-30] [Cited by in Crossref: 35] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
203 Gut P, Fischbach J, Kamiński G, Ruchała M. Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas. Contemp Oncol (Pozn) 2012;16:371-5. [PMID: 23788913 DOI: 10.5114/wo.2012.31764] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
204 Mukherjee E, Carroll R, Matfin G. Endocrine and metabolic emergencies: hypoglycaemia. Ther Adv Endocrinol Metab 2011;2:81-93. [PMID: 23148173 DOI: 10.1177/2042018811401644] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
205 Rossi RE, Massironi S, Spampatti MP, Conte D, Ciafardini C, Cavalcoli F, Peracchi M. Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg 2012;16:1981-92. [PMID: 22829240 DOI: 10.1007/s11605-012-1951-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
206 Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer 2012;19:615-23. [PMID: 22736724 DOI: 10.1530/ERC-11-0382] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
207 Pecori Giraldi F, Pagliardini L, Cassarino M, Martucci F, Sesta A, Castelli L, Montanari E, Schmid H, Cavagnini F. Stimulatory effect of SOM230 on human and rat adrenal corticosteroid secretion in vitro. General and Comparative Endocrinology 2012;178:436-9. [DOI: 10.1016/j.ygcen.2012.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
208 Waser B, Cescato R, Liu Q, Kao YJ, Körner M, Christ E, Schonbrunn A, Reubi JC. Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients. Am J Pathol 2012;180:1942-9. [PMID: 22538189 DOI: 10.1016/j.ajpath.2012.01.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
209 Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology. 2012;83:117-127. [PMID: 22797357 DOI: 10.1159/000339539] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
210 Wigmore T. Commentary:. Journal of the Intensive Care Society 2012;13:255-255. [DOI: 10.1177/175114371201300317] [Reference Citation Analysis]
211 Sowa-staszczak A, Chrzan R, Pach D, Stefańska A, Tomaszuk M, Buziak-bereza M, Kołodziej M, Przybylik-mazurek E, Hubalewska-dydejczyk A. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors? Clinical Imaging 2012;36:360-4. [DOI: 10.1016/j.clinimag.2011.11.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
212 Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 2012;13:24-34. [PMID: 22198808 DOI: 10.1007/s11864-011-0172-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
213 Grozinsky-Glasberg S, Shimon I, Rubinfeld H. The role of cell lines in the study of neuroendocrine tumors. Neuroendocrinology. 2012;96:173-187. [PMID: 22538498 DOI: 10.1159/000338793] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
214 Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17:747-755. [PMID: 22628056 DOI: 10.1634/theoncologist.2011-0458] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
215 Zhou C, Zhang J, Zheng Y, Zhu Z. Pancreatic neuroendocrine tumors: a comprehensive review. Int J Cancer 2012;131:1013-22. [PMID: 22437917 DOI: 10.1002/ijc.27543] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
216 Gao F, Visvardis EE, Sita-Lumsden A, Waxman J. Advances in the treatment of pancreatic neuroendocrine tumours. QJM 2012;105:819-22. [PMID: 22383691 DOI: 10.1093/qjmed/hcs032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
217 van Os E, Schrama M, Kamphuis K, de Herder WW, Damen GM. Abdominal pain and liver lesions in Zollinger-Ellison syndrome. J Pediatr Gastroenterol Nutr 2012;54:435-7. [PMID: 21760542 DOI: 10.1097/MPG.0b013e31822c42d9] [Reference Citation Analysis]
218 Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-176. [PMID: 22262022 DOI: 10.1159/000335597] [Cited by in Crossref: 588] [Cited by in F6Publishing: 636] [Article Influence: 53.5] [Reference Citation Analysis]
219 Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R;  Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119. [PMID: 22261919 DOI: 10.1159/000335591] [Cited by in Crossref: 374] [Cited by in F6Publishing: 408] [Article Influence: 34.0] [Reference Citation Analysis]
220 Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012;23:2335-2341. [PMID: 22317769 DOI: 10.1093/annonc/mdr614] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
221 Talme T, Sundqvist K. The Effects of Somatostatin on Immune Cells, Functions and Diseases. In: Levite M, editor. Nerve-Driven Immunity. Vienna: Springer; 2012. pp. 203-25. [DOI: 10.1007/978-3-7091-0888-8_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Miljković MD, Girotra M, Abraham RR, Erlich RB. Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci 2012;57:9-18. [PMID: 21938486 DOI: 10.1007/s10620-011-1854-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
223 Literaturhinweise und Internetadressen. Facharzt Hämatologie Onkologie 2012. [DOI: 10.1016/b978-3-437-21212-3.10048-7] [Reference Citation Analysis]
224 Moo-young TA, Prinz RA. Endocrine tumors of the pancreas. Blumgart's Surgery of the Liver, Pancreas and Biliary Tract 2012. [DOI: 10.1016/b978-1-4377-1454-8.00061-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
225 Tanaka H, Naoe H, Yokomine K, Nagahama H, Sakurai K, Tanaka M, Onoue K, Tamura F, Okajima H, Inomata Y, Iyama K, Sasaki Y. A case of non-functioning pancreatic neuroendocrine carcinoma with diffuse multiple liver metastases treated by distal pancreatectomy with splenectomy and simultaneous living-donor liver transplantation. Journal of the Japan Pancreas Society 2012;27:69-79. [DOI: 10.2958/suizo.27.69] [Reference Citation Analysis]
226 Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB; UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6-32. [PMID: 22052063 DOI: 10.1136/gutjnl-2011-300831] [Cited by in Crossref: 387] [Cited by in F6Publishing: 379] [Article Influence: 35.2] [Reference Citation Analysis]
227 Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: Evaluation of efficacy and toxicity. Lung Cancer 2011;74:492-6. [DOI: 10.1016/j.lungcan.2011.05.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
228 Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine 2012;41:40-52. [DOI: 10.1007/s12020-011-9562-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
229 Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Van Uum S, Wong R. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010;17:49-64. [PMID: 20567626 DOI: 10.3747/co.v17i3.484] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
230 Valentino J, Evers BM. Recent advances in the diagnosis and treatment of gastrointestinal carcinoids. Adv Surg 2011;45:285-300. [PMID: 21954695 DOI: 10.1016/j.yasu.2011.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
231 Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21 Suppl 7:vii72-vii80. [PMID: 20943646 DOI: 10.1093/annonc/mdq290] [Cited by in Crossref: 69] [Cited by in F6Publishing: 83] [Article Influence: 5.8] [Reference Citation Analysis]
232 Mima K, Beppu T, Murata A, Otao R, Miyake K, Okabe H, Masuda T, Okabe K, Sugiyama S, Chikamoto A, Ishiko T, Takamori H, Baba H. Primary neuroendocrine tumor in the liver treated by hepatectomy: report of a case. Surg Today 2011;41:1655-60. [PMID: 21969201 DOI: 10.1007/s00595-011-4497-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
233 Öberg K. Which therapy for which patient? Advances in Neuroendocrine Tumor Management 2011. [DOI: 10.2217/ebo.11.90] [Reference Citation Analysis]
234 Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther 2011;28:825-41. [PMID: 21964965 DOI: 10.1007/s12325-011-0062-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
235 de Herder WW. Somatostatin analogs. Advances in Neuroendocrine Tumor Management 2011. [DOI: 10.2217/ebo.11.101] [Reference Citation Analysis]
236 Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol). 2012;24:282-293. [PMID: 21907552 DOI: 10.1016/j.clon.2011.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
237 Salazar R, Reidy-Lagunes D, Yao J. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs 2011;71:841-52. [PMID: 21568362 DOI: 10.2165/11585500-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
238 Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O'Dorisio TM, Howe JR. Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution. Ann Surg Oncol 2012;19:966-72. [PMID: 21845496 DOI: 10.1245/s10434-011-1997-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
239 de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA. New therapeutic options for metastatic malignant insulinomas: New therapeutic options for metastatic malignant insulinomas. Clinical Endocrinology 2011;75:277-84. [DOI: 10.1111/j.1365-2265.2011.04145.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
240 Gupta S, Engstrom PF, Cohen SJ. Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors. Clin Colorectal Cancer 2011;10:298-309. [PMID: 21813338 DOI: 10.1016/j.clcc.2011.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
241 Taşdelen B, Ergun A, Büyükkaya F. Rapid isocratic HPLC investigation of radiochemical purity for 90Y-DOTATATE. J Radioanal Nucl Chem 2011;289:573-575. [DOI: 10.1007/s10967-011-1119-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
242 Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol 2011;122:190-8. [PMID: 21621706 DOI: 10.1016/j.ygyno.2011.04.011] [Cited by in Crossref: 192] [Cited by in F6Publishing: 205] [Article Influence: 16.0] [Reference Citation Analysis]
243 Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, Severino R, Bellucci MC, Camera LM, Lombardi G. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest. 2012;35:326-331. [PMID: 21757992 DOI: 10.3275/7869] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
244 Pavel M. [Metastatic neuroendocrine neoplasms. Non-surgical treatment strategies]. Chirurg 2011;82:612-7. [PMID: 21735357 DOI: 10.1007/s00104-011-2073-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
245 Vinjamaram S, Iyer R. Sandostatin desensitization–a strategy useful for patients with carcinoid tumors, intolerant to sandostatin. Cancer Chemother Pharmacol 2011;68:225-226. [DOI: 10.1007/s00280-010-1436-4] [Reference Citation Analysis]
246 Pavel M. Medizinische Therapie und Chemotherapie von neuroendokrinen Tumoren. Onkologe 2011;17:592-601. [DOI: 10.1007/s00761-011-2053-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
247 Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011;34:235-42. [PMID: 21585408 DOI: 10.1111/j.1365-2036.2011.04693.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
248 Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4:29. [PMID: 21672194 DOI: 10.1186/1756-8722-4-29] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
249 Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:153-162, ix. [PMID: 21349416 DOI: 10.1016/j.ecl.2010.12.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
250 Vinik AI, Gonzales MR. New and emerging syndromes due to neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:19-63, vii. [PMID: 21349410 DOI: 10.1016/j.ecl.2010.12.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
251 Capdevila J, Salazar R, Halperín I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011;30 Suppl 1:27-34. [PMID: 21311955 DOI: 10.1007/s10555-011-9290-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
252 Castellano D, Salazar R, Raymond E. Future perspectives on neuroendocrine tumors. Cancer Metastasis Rev 2011;30 Suppl 1:35-40. [PMID: 21327890 DOI: 10.1007/s10555-011-9294-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
253 Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, Kołodziej M, Mikołajczak R, Pawlak D, Hubalewska-Dydejczyk A. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging 2011;38:1669-74. [PMID: 21559978 DOI: 10.1007/s00259-011-1835-8] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 5.7] [Reference Citation Analysis]
254 Leja J, Yu D, Nilsson B, Gedda L, Zieba A, Hakkarainen T, Åkerström G, Öberg K, Giandomenico V, Essand M. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther 2011;18:1052-62. [PMID: 21490682 DOI: 10.1038/gt.2011.54] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
255 Strosberg JR, Cheema A, Kvols LK. A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. Cancer Control 2011;18:127-37. [DOI: 10.1177/107327481101800207] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
256 Komborozos VA. Carcinoid tumours of the small bowel colon and rectum. Hellenic J Surg 2011;83:12-20. [DOI: 10.1007/s13126-011-0003-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
257 Faivre S, Sablin MP, Dreyer C, Raymond E. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin North Am. 2010;39:811-826. [PMID: 21095547 DOI: 10.1016/j.ecl.2010.09.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
258 Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594-618. [PMID: 21167379 DOI: 10.1053/j.seminoncol.2010.10.014] [Cited by in Crossref: 127] [Cited by in F6Publishing: 135] [Article Influence: 10.6] [Reference Citation Analysis]
259 Wade AN, Cheng G, Teitelbaum U, Patel AA, Alavi A, Rickels MR. Amelioration of hypoglycemia with octreotide therapy in metastatic insulinoma with positive octreotide scan. Pancreas 2011;40:173-5. [PMID: 21160385 DOI: 10.1097/MPA.0b013e3181fa46f2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
260 Strosberg J. Management of Neuroendocrine Tumor Hormonal Syndromes. Neuroendocrine Tumors 2011. [DOI: 10.1007/978-1-60327-997-0_7] [Reference Citation Analysis]
261 Boonsirikamchai P, Asran MKA, Charnsangavej C. Imaging of Neuroendocrine Tumors. Neuroendocrine Tumors 2011. [DOI: 10.1007/978-1-60327-997-0_5] [Reference Citation Analysis]
262 Arslan N, Emi M, Alagöz E, Üstünsöz B, Oysul K, Arpacı F, Uğurel Ş, Beyzadeoğlu M, Özgüven A. Selective intraarterial radionuclide therapy with yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: Initial experience at a single center. VSP 2011;68:341-8. [DOI: 10.2298/vsp1104341a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
263 Eriksson B. Medical Management of Islet Cell Carcinoma. Neuroendocrine Tumors 2011. [DOI: 10.1007/978-1-60327-997-0_9] [Reference Citation Analysis]
264 Fiebrich HB, Van Den Berg G, Kema IP, Links TP, Kleibeuker JH, Van Beek AP, Walenkamp AM, Sluiter WJ, De Vries EG. Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Aliment Pharmacol Ther 2010;32:1398-404. [PMID: 21050243 DOI: 10.1111/j.1365-2036.2010.04479.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
265 Okuma Y, Shimokawa T, Takagi Y, Hosomi Y, Iguchi M, Okamura T, Shibuya M. S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer 2010;70:357-63. [DOI: 10.1016/j.lungcan.2010.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
266 Cirillo F. Metastatic Paraganglioma and Treatment with Sunitinib: A Case Report. Tumori 2010;96:1022-1027. [DOI: 10.1177/548.6526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
267 Joseph S, Li G, Lindholm E, Zhou Y, Go VL, Vinik AI, O'Dorisio TM, Mamikunian G, Woltering EA. A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy. Pancreas 2010;39:964-6. [PMID: 20467346 DOI: 10.1097/MPA.0b013e3181db01a8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
268 Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90. Appl Radiat Isot 2011;69:52-5. [PMID: 20869877 DOI: 10.1016/j.apradiso.2010.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
269 Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE, Peracchi M. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol 2010;105:2072-8. [PMID: 20372113 DOI: 10.1038/ajg.2010.154] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
270 Díez JJ, Iglesias P. Pruebas de imagen en el diagnóstico de los tumores neuroendocrinos. Medicina Clínica 2010;135:319-25. [DOI: 10.1016/j.medcli.2009.04.048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
271 Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742-53, 753.e1. [PMID: 20637207 DOI: 10.1053/j.gastro.2010.07.002] [Cited by in Crossref: 128] [Cited by in F6Publishing: 138] [Article Influence: 9.8] [Reference Citation Analysis]
272 Cheng SP, Doherty GM. Rare neuroendocrine tumors of the pancreas. Cancer Treat Res 2010;153:253-70. [PMID: 19957229 DOI: 10.1007/978-1-4419-0857-5_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
273 Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB 3rd, Pommier RF; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas 2010;39:767-74. [PMID: 20664474 DOI: 10.1097/MPA.0b013e3181ec1261] [Cited by in Crossref: 185] [Cited by in F6Publishing: 175] [Article Influence: 14.2] [Reference Citation Analysis]
274 Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 2010;12:361-79. [PMID: 20662787 DOI: 10.1111/j.1477-2574.2010.00175.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 112] [Article Influence: 8.2] [Reference Citation Analysis]
275 Vinik AI, Anthony L, Boudreaux JP, Go VL, O'Dorisio TM, Ruszniewski P, Woltering EA. Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas 2010;39:801-18. [PMID: 20664478 DOI: 10.1097/MPA.0b013e3181ea5839] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
276 Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT; North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-52. [PMID: 20664472 DOI: 10.1097/MPA.0b013e3181ebb168] [Cited by in Crossref: 387] [Cited by in F6Publishing: 386] [Article Influence: 29.8] [Reference Citation Analysis]
277 Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-34. [PMID: 20664471 DOI: 10.1097/MPA.0b013e3181ebaffd] [Cited by in Crossref: 184] [Cited by in F6Publishing: 189] [Article Influence: 14.2] [Reference Citation Analysis]
278 Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(24): 2963-2970 [PMID: 20572298 DOI: 10.3748/wjg.v16.i24.2963] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 87] [Article Influence: 6.3] [Reference Citation Analysis]
279 van der Hoek J, Lamberts SW, Hofland LJ. The somatostatin receptor subtype 5 in neuroendocrine tumours. Expert Opin Investig Drugs 2010;19:385-99. [PMID: 20151855 DOI: 10.1517/13543781003604710] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
280 Poncet G, Faucheron JL, Walter T. Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol 2010; 16(14): 1696-1706 [PMID: 20380000 DOI: 10.3748/wjg.v16.i14.1696] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
281 Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, Långström B. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass. Nuclear Medicine and Biology 2010;37:265-75. [DOI: 10.1016/j.nucmedbio.2009.11.008] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 7.4] [Reference Citation Analysis]
282 Oberg K. Antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol 2010;6:188-9. [DOI: 10.1038/nrendo.2010.3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
283 Landerholm K, Falkmer S, Järhult J. Epidemiology of Small Bowel Carcinoids in a Defined Population. World J Surg 2010;34:1500-5. [DOI: 10.1007/s00268-010-0519-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
284 Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab 2010;95:2343-50. [PMID: 20228164 DOI: 10.1210/jc.2009-2487] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
285 Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19. [PMID: 20196864 DOI: 10.1186/1756-9966-29-19] [Cited by in Crossref: 89] [Cited by in F6Publishing: 97] [Article Influence: 6.8] [Reference Citation Analysis]
286 Cirillo F. Role of Somatostatin Analogs in the Management of Neuroendocrine Tumors. Tumori 2010;96:191-197. [DOI: 10.1177/030089161009600202] [Reference Citation Analysis]
287 Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V, Pederzoli P. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17:1621-1627. [PMID: 22319653 DOI: 10.1155/2012/782672] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
288 Borbath I, Leclercq IA, Sempoux C, Abarca-quinones J, Desaeger C, Horsmans Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chemico-Biological Interactions 2010;183:238-48. [DOI: 10.1016/j.cbi.2009.10.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
289 Jensen RT, Norton JA. Endocrine Tumors of the Pancreas and Gastrointestinal Tract. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00032-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
290 Lombard-bohas C, Cassier P. Pancréas. Tumeurs malignes rares 2010. [DOI: 10.1007/978-2-287-72070-3_33] [Reference Citation Analysis]
291 Liu DM, Kennedy A, Turner D, Rose SC, Kee ST, Whiting S, Murthy R, Nutting C, Heran M, Lewandowski R. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol. 2009;32:200-215. [PMID: 19346815 DOI: 10.1097/coc.0b013e318172b3b6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
292 Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69-76. [PMID: 19933912 DOI: 10.1200/jco.2009.24.2669] [Cited by in Crossref: 478] [Cited by in F6Publishing: 521] [Article Influence: 34.1] [Reference Citation Analysis]
293 Osamura RY. Roles of pathologists in molecular targeted cancer therapy. J Cell Mol Med 2009;13:4286-90. [PMID: 19891708 DOI: 10.1111/j.1582-4934.2009.00960.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
294 Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 2009;9:388. [PMID: 19886987 DOI: 10.1186/1471-2407-9-388] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 3.5] [Reference Citation Analysis]
295 Capurso G, Fazio N, Festa S, Panzuto F, De Braud F, Delle Fave G. Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. Critical Reviews in Oncology/Hematology 2009;72:110-24. [DOI: 10.1016/j.critrevonc.2009.01.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
296 Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther 2009;30:733-40. [PMID: 19573169 DOI: 10.1111/j.1365-2036.2009.04083.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
297 Peros G, Sakorafas GH, Konstantoudakis G, Giannopoulos GA, Petropoulou K, Parasi A. Duodeno-pancreatic neuroendocrine tumours. Eur J Cancer Care (Engl) 2010;19:393-402. [PMID: 19708940 DOI: 10.1111/j.1365-2354.2007.00894.x] [Reference Citation Analysis]
298 Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663. [PMID: 19704057 DOI: 10.1200/jco.2009.22.8510] [Cited by in Crossref: 1609] [Cited by in F6Publishing: 1759] [Article Influence: 114.9] [Reference Citation Analysis]
299 Ong SL, Garcea G, Pollard CA, Furness PN, Steward WP, Rajesh A, Spencer L, Lloyd DM, Berry DP, Dennison AR. A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology 2009;9:583-600. [PMID: 19657214 DOI: 10.1159/000212085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
300 Mcpherson A, Regan J, Jackson N. The Case Report and Palliative Management of a Patient with Carcinoid Syndrome and Crises. Journal of Palliative Medicine 2009;12:743-745. [DOI: 10.1089/jpm.2009.0068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
301 Woo K, Imasogie N, Bruni I, Singh S. Anaesthetic management of a pregnant woman with carcinoid disease. International Journal of Obstetric Anesthesia 2009;18:272-5. [DOI: 10.1016/j.ijoa.2009.01.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
302 Castinetti F, Saveanu A, Morange I, Brue T. Lanreotide for the treatment of acromegaly. Adv Ther 2009;26:600-12. [PMID: 19533047 DOI: 10.1007/s12325-009-0035-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
303 Srirajaskanthan R, Toumpanakis C, Meyer T, Caplin ME. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. Aliment Pharmacol Ther 2009;29:1143-54. [PMID: 19298583 DOI: 10.1111/j.1365-2036.2009.03988.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
304 Grande C, Haller DG. Gastrointestinal stromal tumors and neuroendocrine tumors. Semin Oncol Nurs. 2009;25:48-60. [PMID: 19217505 DOI: 10.1016/j.soncn.2008.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
305 Jackson LN, Chen LA, Larson SD, Silva SR, Rychahou PG, Boor PJ, Li J, Defreitas G, Stafford WL, Townsend CM Jr, Evers BM. Development and characterization of a novel in vivo model of carcinoid syndrome. Clin Cancer Res 2009;15:2747-55. [PMID: 19336516 DOI: 10.1158/1078-0432.CCR-08-2346] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
306 Alberini JL, Wartski M, Edeline V, Madar O, Banayan S, Bellet D, Pecking AP. Molecular Imaging of Neuroendocrine Cancer by Fusion SPET/CT. In: Leong SPL, editor. From Local Invasion to Metastatic Cancer. Totowa: Humana Press; 2009. pp. 169-75. [DOI: 10.1007/978-1-60327-087-8_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
307 Modlin IM, Kidd M, Drozdov I, Siddique ZL, Gustafsson BI. Pharmacotherapy of neuroendocrine cancers. Expert Opin Pharmacother. 2008;9:2617-2626. [PMID: 18803449 DOI: 10.1517/14656566.9.15.2617] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
308 Falchetti A. Fisiopatologia e trattamento nelle forme familiari dell'Iperparatiroidismo Primitivo. Giornale di Tecniche Nefrologiche e Dialitiche 2009;21:18-24. [DOI: 10.1177/039493620902100104] [Reference Citation Analysis]
309 Bendelow J, Jones L, Poston GJ. Carcinoid Liver Metastases: The Carcinoid Syndrome. Liver Metastases 2009. [DOI: 10.1007/978-1-84628-947-7_13] [Reference Citation Analysis]
310 Azumi Y, Isaji S, Kato H, Kuriyama N, Kishiwada M, Hamada T, Mizuno S, Usui M, Sakurai H, Tabata M, Inoue H, Katsurahara M, Takei Y, Uchida K, Shiraishi T. A case of a tiny (1.2cm) non-functioning pancreatic endocrine tumor invading the main pancreatic duct successfully treated by laparoscopy-assisted distal pancreatectomy with splenectomy. Journal of the Japan Pancreas Society 2009;24:717-725. [DOI: 10.2958/suizo.24.717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
311 Imamura M, Komoto I. Gastrinoma. Endocrine Surgery 2009. [DOI: 10.1007/978-1-84628-881-4_38] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
312 Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, Del Basso De Caro ML, Lombardi G, De Rosa G, Colao A. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. Clinical Endocrinology 2008;69:756-62. [DOI: 10.1111/j.1365-2265.2008.03301.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
313 Kvols LK. Revisiting C.G. Moertel's land of small tumors. J Clin Oncol. 2008;26:5005-5007. [PMID: 18838695 DOI: 10.1200/jco.2008.19.2161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
314 Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008; 14(35): 5377-5384 [PMID: 18803349 DOI: 10.3748/wjg.14.5377] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 119] [Article Influence: 7.1] [Reference Citation Analysis]
315 King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921-929. [PMID: 18618495 DOI: 10.1002/cncr.23685] [Cited by in Crossref: 207] [Cited by in F6Publishing: 220] [Article Influence: 13.8] [Reference Citation Analysis]
316 Bégu-le Corroller A, Valéro R, Moutardier V, Henry J, Le Treut Y, Gueydan M, De Micco C, Sierra M, Conte-devolx B, Oliver C, Raccah D, Favre R, Digue L, Heim M, Seitz J, Delpero J, Vialettes B. Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: A retrospective 35-year study of 12 patients. Diabetes & Metabolism 2008;34:343-8. [DOI: 10.1016/j.diabet.2008.01.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
317 Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403-3410. [PMID: 18612155 DOI: 10.1200/jco.2007.15.9020] [Cited by in Crossref: 467] [Cited by in F6Publishing: 510] [Article Influence: 31.1] [Reference Citation Analysis]
318 Khan MU, Coleman RE. Diagnosis and therapy of carcinoid tumors—current state of the art and future directions. Nuclear Medicine and Biology 2008;35:S77-91. [DOI: 10.1016/j.nucmedbio.2008.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
319 Unger N, Serdiuk I, Sheu S, Walz MK, Schulz S, Saeger W, Schmid KW, Mann K, Petersenn S. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol 2008;68:850-7. [DOI: 10.1111/j.1365-2265.2007.03124.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
320 Niccoli-sire P, Ruszniewski P. RENATEN : Réseau national de prise en charge des tumeurs (neuro-)endocrines malignes rares sporadiques et héréditaires. Oncologie 2008;10:398-405. [DOI: 10.1007/s10269-008-0916-1] [Reference Citation Analysis]
321 Daskalakis M, Henne K, Henß H, Martens U, Digel W, Engelhardt R, Otto F, Deschler B, Berger DP, Allgaier H, Harder J, Behringer D, Waller C, Trepel M, Runnebaum I, Weissenberger C, Spyridonidis A, Schultze-seemann W, Schrenk K, Neumann H, Reincke M, Seufert J, Schwabe M, Veelken H, Marks R, Finke J, Heinz J, Kleber M. Medical Oncology. Concise Manual of Hematology and Oncology. [DOI: 10.1007/978-3-540-73277-8_8] [Reference Citation Analysis]
322 Nasir A, Gardner NM, Strosberg J, Ahmad N, Choi J, Malafa MP, Coppola D, Kwekkeboom DJ, Teunissen JJ, Kvols LK. Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. Pancreas 2008;36:309-13. [PMID: 18362846 DOI: 10.1097/MPA.0b013e31815b321c] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
323 Srirajaskanthan R, Toubanakis C, Dusmet M, Caplin M. A review of thymic tumours. Lung Cancer 2008;60:4-13. [DOI: 10.1016/j.lungcan.2008.01.014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
324 Auernhammer CJ, Göke B. Medical treatment of gastrinomas. Wien Klin Wochenschr 2007;119:609-15. [PMID: 17985097 DOI: 10.1007/s00508-007-0877-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
325 Bendelow J, Apps E, Jones L, Poston G. Carcinoid syndrome. European Journal of Surgical Oncology (EJSO) 2008;34:289-96. [DOI: 10.1016/j.ejso.2007.07.202] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
326 Goldin SB, Aston J, Wahi MM. Sporadically occurring functional pancreatic endocrine tumors: review of recent literature. Curr Opin Oncol 2008;20:25-33. [PMID: 18043253 DOI: 10.1097/CCO.0b013e3282f290af] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
327 Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors. JCO 2008;26:963-70. [DOI: 10.1200/jco.2007.12.7431] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 5.2] [Reference Citation Analysis]
328 de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008;35:749-755. [PMID: 18210106 DOI: 10.1007/s00259-007-0691-z] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
329 Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008;190:67-73. [PMID: 18094295 DOI: 10.2214/ajr.07.2550] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 6.3] [Reference Citation Analysis]
330 Shibata C, Funayama Y, Sasaki I. Pancreatic Endocrine Tumors: Epidemiology, Pathology, Pathophysiology, and Diagnosis. Diseases of the Pancreas. [DOI: 10.1007/978-3-540-28656-1_68] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
331 Izumiyama H, Hirata Y. Imaging modalities used in pancreatic endocrine tumors. Journal of the Japan Pancreas Society 2008;23:665-670. [DOI: 10.2958/suizo.23.665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
332 Takano K. Somatostatin analogue treatment for neuroendocrine tumors. Journal of the Japan Pancreas Society 2008;23:710-715. [DOI: 10.2958/suizo.23.710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
333 Champaneria MC, Modlin IM, Latich I, Bornschein J, Drozdov I, Kidd M. Somatostatin Analogue Therapy. Cancer Drug Discovery and Development. [DOI: 10.1007/978-1-59745-337-0_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
334 Volante M, Rosas R, Allìa E, Granata R, Baragli A, Muccioli G, Papotti M. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol. 2008;286:219-229. [PMID: 18248880 DOI: 10.1016/j.mce.2007.12.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
335 Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M, Grossman AB. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2008;87:168-81. [PMID: 18025810 DOI: 10.1159/000111501] [Cited by in Crossref: 83] [Cited by in F6Publishing: 91] [Article Influence: 5.2] [Reference Citation Analysis]
336 O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008;34:324-332. [PMID: 17967523 DOI: 10.1016/j.ejso.2007.07.209] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
337 Dalm VA, Hofland LJ, Lamberts SW. Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field. Mol Cell Endocrinol 2008;286:262-77. [PMID: 17942217 DOI: 10.1016/j.mce.2007.09.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
338 Healy ML, Dawson SJ, Murray RM, Zalcberg J, Jefford M. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. Intern Med J. 2007;37:406-409. [PMID: 17535385 DOI: 10.1111/j.1445-5994.2007.01371.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
339 Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2007;12:253-70. [PMID: 17604500 DOI: 10.1517/14728214.12.2.253] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
340 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i13.3164] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
341 Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, Mcnicol A, Nilsson O, Perren A, Scarpa A, Scoazec J, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62. [DOI: 10.1007/s00428-007-0452-1] [Cited by in Crossref: 680] [Cited by in F6Publishing: 542] [Article Influence: 42.5] [Reference Citation Analysis]
342 Müssig K, Petersenn S, Wehrmann M, Horger M, Vierling P, Häring HU, Gallwitz B. Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia. Eur J Gastroenterol Hepatol 2007;19:719-23. [PMID: 17625444 DOI: 10.1097/01.meg.0000223908.00987.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
343 Nakakura EK, Venook AP, Bergsland EK. Systemic and Regional Nonsurgical Therapy—What Is the Optimal Strategy for Metastatic Neuroendocrine Cancer? Surgical Oncology Clinics of North America 2007;16:639-51. [DOI: 10.1016/j.soc.2007.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
344 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170 [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 47] [Article Influence: 2.5] [Reference Citation Analysis]
345 Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:69-85. [PMID: 17382266 DOI: 10.1016/j.beem.2006.12.003] [Cited by in Crossref: 119] [Cited by in F6Publishing: 127] [Article Influence: 7.4] [Reference Citation Analysis]
346 Fröjd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes 2007;5:18. [PMID: 17428340 DOI: 10.1186/1477-7525-5-18] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 4.6] [Reference Citation Analysis]
347 Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007;16:219-24. [PMID: 17243941 DOI: 10.1517/13543784.16.2.219] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
348 Williams GT. Endocrine tumours of the gastrointestinal tract-selected topics. Histopathology. 2007;50:30-41. [PMID: 17204019 DOI: 10.1111/j.1365-2559.2006.02570.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
349 O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP, Caplin M, Jensen R, Eriksson B; Frascati Consensus Conference., European Neuroendocrine Tumor Society. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006;84:189-95. [PMID: 17312379 DOI: 10.1159/000098011] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 5.7] [Reference Citation Analysis]
350 Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007;85:54-60. [PMID: 17310129 DOI: 10.1159/000100057] [Cited by in Crossref: 113] [Cited by in F6Publishing: 122] [Article Influence: 7.1] [Reference Citation Analysis]
351 Rigabert J, De Clermont H. [Diagnostic procedures and more particularly, place of scintigraphy in neuroendocrine tumors, example of vipoma in MEN 1]. Ann Endocrinol (Paris) 2007;68:199-203. [PMID: 17292846 DOI: 10.1016/j.ando.2006.11.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
352 Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 2006;17:601-8. [PMID: 16917205 DOI: 10.1097/01.cad.0000210335.95828.ed] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
353 Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247. [PMID: 16762613 DOI: 10.1053/j.semnuclmed.2006.03.007] [Cited by in Crossref: 300] [Cited by in F6Publishing: 320] [Article Influence: 18.8] [Reference Citation Analysis]
354 Nestor J. Peptide and Protein Drugs: Issues and Solutions. Comprehensive Medicinal Chemistry II 2007. [DOI: 10.1016/b0-08-045044-x/00050-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
355 Vezzosi D, Bournet B, Buscail L. Somatostatine en pathologie tumorale pancréatique. EMC - Hépatologie 2007;2:1-5. [DOI: 10.1016/s1155-1976(07)22883-9] [Reference Citation Analysis]
356 Caron P. Lanreotide Autogel®in acromegaly and neuroendocrine tumors. Therapy 2007;4:9-29. [DOI: 10.2217/14750708.4.1.9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
357 Marazuela Azpíroz M, Ignacio Bernabeu Morón E. Tratamiento farmacológico de los tumores neuroendocrinos gastroenteropancreáticos: análogos de somatostatina. Endocrinología y Nutrición 2007;54:44-50. [DOI: 10.1016/s1575-0922(07)71518-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
358 Engelhardt D, Pape U, Plöckinger U, Wiedenmann B. Malignome endokriner Organe. Facharzt Hämatologie Onkologie 2007. [DOI: 10.1016/b978-343723770-6.50026-0] [Reference Citation Analysis]
359 Weber K, Lin J, Prinz R. Endocrine Tumors of the Pancreas: Clinical Picture, Diagnosis, and Therapy. Surgery of the Liver, Biliary Tract and Pancreas 2007. [DOI: 10.1016/b978-1-4160-3256-4.50069-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
360 Levy AD, Sobin LH. Gastrointestinal Carcinoids: Imaging Features with Clinicopathologic Comparison. RadioGraphics 2007;27:237-57. [DOI: 10.1148/rg.271065169] [Cited by in Crossref: 123] [Cited by in F6Publishing: 131] [Article Influence: 7.7] [Reference Citation Analysis]
361 Sanabria C, Pérez-ferre N, Lecumberri E, Miguel PD. Gastrinoma. Endocrinología y Nutrición 2007;54:21-30. [DOI: 10.1016/s1575-0922(07)71515-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
362 Dalgleish A, Copier J. New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib. Targ Oncol 2007;2:17-29. [DOI: 10.1007/s11523-006-0040-3] [Reference Citation Analysis]
363 Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, Malafa M, Shibata D. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14:780-785. [PMID: 17146740 DOI: 10.1245/s10434-006-9148-z] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 3.4] [Reference Citation Analysis]
364 Couvelard A, Scoazec J. Une classification TNM pour les tumeurs endocrines digestives: recommandations de l’European Neuroendocrine Tumor Society (2006). Annales de Pathologie 2006;26:413-7. [DOI: 10.1016/s0242-6498(06)70748-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
365 Stephen AE, Hodin RA. Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin N Am. 2006;15:497-510. [PMID: 16882494 DOI: 10.1016/j.soc.2006.05.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
366 Volante M, Rindi G, Papotti M. The grey zone between pure (neuro) endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch. 2006;449:499-506. [PMID: 17033797 DOI: 10.1007/s00428-006-0306-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
367 Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728-734. [PMID: 16945767 DOI: 10.1016/s1470-2045(06)70801-4] [Cited by in Crossref: 183] [Cited by in F6Publishing: 137] [Article Influence: 10.8] [Reference Citation Analysis]
368 Salazar R, Villabona C, Fabregat J. [Gastrointestinal and pancreatic neuroendocrine tumors]. Med Clin (Barc) 2006;127:227-31. [PMID: 16938245 DOI: 10.1157/13091016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
369 Woltering EA, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas 2006;33:250-4. [PMID: 17003646 DOI: 10.1097/01.mpa.0000235302.73615.d4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
370 Lewis B, Keuchel M, Caselitz J. Malignant Tumors. Atlas of Video Capsule Endoscopy. [DOI: 10.1007/3-540-35686-x_25] [Reference Citation Analysis]
371 Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401. [PMID: 16967267 DOI: 10.1007/s00428-006-0250-1] [Cited by in Crossref: 1112] [Cited by in F6Publishing: 1183] [Article Influence: 65.4] [Reference Citation Analysis]
372 Davì MV, Bodei L, Francia G, Bartolomei M, Oliani C, Scilanga L, Reghellin D, Falconi M, Paganelli G, Lo Cascio V, Ferdeghini M. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest 2006;29:563-7. [PMID: 16840837 DOI: 10.1007/BF03344149] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
373 Jahng AW, Liao SS. Successful Palliation with Octreotide of a Neuroendocrine Syndrome from Malignant Melanoma. Journal of Pain and Symptom Management 2006;32:191-5. [DOI: 10.1016/j.jpainsymman.2006.02.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
374 Whitman HH, Fishman EK, Oberg K, Wildman JM, Long AL. Catecholamine-Secreting Metastatic Carcinoid as Differential Diagnosis in Pheochromocytoma: Clinical, Laboratory, and Imaging Clues in the Search for the Lurking Neuroendocrine Tumor (NET). Annals of the New York Academy of Sciences 2006;1073:59-78. [DOI: 10.1196/annals.1353.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
375 Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006;13:72-8. [PMID: 16508629 DOI: 10.1177/107327480601300110] [Cited by in Crossref: 111] [Cited by in F6Publishing: 120] [Article Influence: 6.5] [Reference Citation Analysis]
376 Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, Kelley ST, Centeno BA, Coppola D, Malafa ME, Yeatman TJ, Kvols LK. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control 2006;13:52-60. [PMID: 16508627 DOI: 10.1177/107327480601300108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
377 Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17:1733-1742. [PMID: 16801334 DOI: 10.1093/annonc/mdl105] [Cited by in Crossref: 209] [Cited by in F6Publishing: 223] [Article Influence: 12.3] [Reference Citation Analysis]
378 Fazio N, de Braud F, Delle Fave G, Öberg K. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 2007;18:13-9. [PMID: 16798833 DOI: 10.1093/annonc/mdl144] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 4.0] [Reference Citation Analysis]
379 Simon P, Spilcke-liss E, Wallaschofski H. Endocrine Tumors of the Pancreas. Endocrinology and Metabolism Clinics of North America 2006;35:431-47. [DOI: 10.1016/j.ecl.2006.02.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
380 Modlin IM, Latich I, Kidd M, Zikusoka M, Eick G. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526-47. [PMID: 16630755 DOI: 10.1016/j.cgh.2005.12.008] [Cited by in Crossref: 109] [Cited by in F6Publishing: 117] [Article Influence: 6.4] [Reference Citation Analysis]
381 Blonski WC, Reddy KR, Shaked A, Siegelman E, Metz DC. Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature. World J Gastroenterol. 2005;11:7676-7683. [PMID: 16437698 DOI: 10.3748/wjg.v11.i48.7676] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
382 Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, Baroni MG. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res 2006;65:120-5. [PMID: 16479142 DOI: 10.1159/000091408] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
383 van der Lely AJ, de Herder WW. Carcinoid syndrome: Diagnosis and medical management. Arq Bras Endocrinol Metabol. 2005;49:850-860. [PMID: 16444370 DOI: 10.1590/s0004-27302005000500028] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
384 Zomerhuis MT, Hussain SM, Feelders RA, van der Lely AJ, de Herder WW. Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome. Neuroendocrinology 2005;82:41-8. [PMID: 16391492 DOI: 10.1159/000090636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
385 Endocrine, Exocrine, and Reproductive Systems. Vascular and Interventional Radiology 2006. [DOI: 10.1016/b978-0-7216-0621-7.50016-0] [Reference Citation Analysis]
386 Matzdorff A, Preiß J, Schmieder A. Endokrine Tumoren. Onkologie integrativ 2006. [DOI: 10.1016/b978-343756420-8.50026-3] [Reference Citation Analysis]
387 Harris AG, Daly AF, Tichomirowa M, Beckers A, Lamberts SW. Somatostatin Analogs in the Gastrointestinal Tract. Handbook of Biologically Active Peptides 2006. [DOI: 10.1016/b978-012369442-3/50158-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
388 Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, Milione M, Cattaruzza MS, Falconi M, David V. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17:461-466. [PMID: 16364959 DOI: 10.1093/annonc/mdj113] [Cited by in Crossref: 98] [Cited by in F6Publishing: 106] [Article Influence: 5.4] [Reference Citation Analysis]
389 Rindi G, Couvelard A, Scoazec J, Bordi C. Évaluation de la malignité dans les tumeurs endocrines digestives : recommandations pratiques. Annales de Pathologie 2005;25:487-98. [DOI: 10.1016/s0242-6498(05)86162-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
390 Woltering EA, Mamikunian PM, Zietz S, Krutzik SR, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 2005;31:392-400. [PMID: 16258376 DOI: 10.1097/01.mpa.0000186249.89081.0d] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
391 Doherty GM. Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol 2005;19:807-17. [PMID: 16253902 DOI: 10.1016/j.bpg.2005.05.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
392 Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:617-36. [PMID: 16183531 DOI: 10.1016/j.bpg.2005.02.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
393 Biering H, Bauditz J, Brenner N, Stein H, Lochs H, Strasburger CJ. Primary neuroendocrine carcinoma of inguinal lymph node. Horm Res 2005;64:16-9. [PMID: 16088203 DOI: 10.1159/000087191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
394 Moschos S, Varanasi S, Kirkwood JM. Interferons in the treatment of solid tumors. Cancer Treat Res 2005;126:207-41. [PMID: 16209068 DOI: 10.1007/0-387-24361-5_9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
395 Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005;241:839-45; discussion 845-6. [PMID: 15912033 DOI: 10.1097/01.sla.0000164073.08093.5d] [Cited by in Crossref: 94] [Cited by in F6Publishing: 99] [Article Influence: 5.2] [Reference Citation Analysis]
396 Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51. [PMID: 15887161 DOI: 10.1053/j.gastro.2005.03.038] [Cited by in Crossref: 562] [Cited by in F6Publishing: 597] [Article Influence: 31.2] [Reference Citation Analysis]
397 Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 2005;128:1668-84. [PMID: 15887158 DOI: 10.1053/j.gastro.2005.03.078] [Cited by in Crossref: 77] [Cited by in F6Publishing: 84] [Article Influence: 4.3] [Reference Citation Analysis]
398 Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa’y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release Lanreotide therapy. World J Gastroenterol 2005; 11(13): 2041-2044 [PMID: 15801004 DOI: 10.3748/wjg.v11.i13.2041] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
399 Banfield A, Green S, Ramage J. Neuroendocrine tumour management: a team approach. British Journal of Hospital Medicine 2005;66:37-42. [DOI: 10.12968/hmed.2005.66.1.17534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
400 Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004;80 Suppl 1:47-50. [PMID: 15477717 DOI: 10.1159/000080741] [Cited by in Crossref: 119] [Cited by in F6Publishing: 138] [Article Influence: 6.3] [Reference Citation Analysis]
401 Öberg K. Management of neuroendocrine tumours. Annals of Oncology 2004;15:iv293-8. [DOI: 10.1093/annonc/mdh942] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
402 Naderi M, Zolghadri S, Yousefnia H, Ramazani A, Jalilian AR. Preclinical Study of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs. Asia Ocean J Nucl Med Biol 2016;4:19-29. [PMID: 27904870 DOI: 10.7508/aojnmb.2016.04.004] [Cited by in F6Publishing: 2] [Reference Citation Analysis]